Additionally, miR-10a enhances the resistance of circulating tumor cells (CTCs) to cisplatin and inhibits the PI3K/Akt pathway by targeting PIK3CA, providing a novel therapeutic target for NSCLC treatment (193). Here, AKT1 is linked to non-small cell lung carcinoma.